Interactions

Displaying 1001 - 1200 of 1240

ARV

Drug 2

Color Code

Drug 1 dose (field_drug_1_dose)

Drug doses

ID	Title	drug 1 Sort descending	drug 1 dose	drug 1 effect	drug 2	drug 2 dose	drug 2 effect	Clinical Effects	Color	Clinical Bottom Line	Management	Alt Agents	Info Source
5910	Raltegravir Famotidine 295	Raltegravir	400 mg BID	Raltegravir AUC increased 45%; Cmax increased 60%	Famotidine	20 mg daily given 2 hours before raltegravir			Green: Administer standard doses	Administer standard doses
5926	Raltegravir G/P 311	Raltegravir	400 mg BID	Raltegravir AUC increased 47%; Cmin increased 164%	Glecaprevir / Pibrentasvir	300 / 120 mg daily	Not reported		Green: Administer standard doses	Administer standard doses
5911	Raltegravir Omeprazole 296	Raltegravir	400 mg Q12H	Raltegravir AUC increased 212%; Cmin increased 46%; Cmax increased 315%	Omeprazole	20 mg daily x 4 days			Green: Administer standard doses	Administer standard doses
5927	Raltegravir SOF/VEL 312	Raltegravir	400 mg BID	Raltegravir Cmin increased 8%; AUC increased 5%.	Sofosbuvir / Velpatasvir	400 mg / 100 mg	Not reported		Green: Administer standard doses	Administer standard doses
5896	Raltegravir RIF 281	Raltegravir	400 mg x 1	Raltegravir AUC decreased 40%; Cmax decreased 38%; Cmin decreased 61%	Rifampin	600 mg daily	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.	Rifabutin
5912	Raltegravir Omeprazole 297	Raltegravir	400 mg BID	Raltegravir AUC increased 39%; Cmax increased 50%; Cmin increased 24%	Omeprazole	20 mg daily	Not reported		Green: Administer standard doses	Administer standard doses
5928	Raltegravir SOF 313	Raltegravir	400 mg daily	No significant change	Sofosbuvir	400 mg x 1	Sofosbuvir Cmax decreased 43%; AUC decreased 27%		Green: Administer standard doses	Administer standard doses
5897	Raltegravir RIF 282	Raltegravir	800 mg BID	Raltegravir AUC increased 27%; Cmax increased 62%; Cmin decreased 53% (all compared to raltegravir 400 mg BID)	Rifampin	600 mg daily	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.	Rifabutin
5913	Raltegravir Ginkgo biloba 298	Raltegravir	400 mg x 1	No significant change	Ginkgo biloba	120 mg BID	Ginkgo biloba AUC increased 21%; Cmax increased 44%		Green: Administer standard doses	Administer standard doses
5929	Raltegravir RPV 314	Raltegravir	400 mg BID	Raltegravir Cmin increased 27%	Rilpivirine	25 mg daily			Green: Administer standard doses	Administer standard doses
5898	Raltegravir RIF 283	Raltegravir	800 mg Q12H	Raltegravir AUC increased 27%; Cmin decreased 53%; Cmax increased 62% (compared to 400 mg raltegravir Q12H when given alone)	Rifampin	600 mg daily			Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.	Rifabutin
5914	Raltegravir ETR 299	Raltegravir	400 mg	Not reported	Etravirine	200 mg	Etravirine AUC increased 10%, Cmin increased 17%		Green: Administer standard doses	Administer standard doses
5930	Raltegravir DRV 315	Raltegravir	400 mg Q12H	Raltegravir AUC decreased 29%; Cmin increased 38%; Cmax decreased 33%	Darunavir	600 mg Q12H with 100 mg ritonavir Q12H			Green: Administer standard doses	Administer standard doses
5899	Raltegravir RPT 284	Raltegravir	400 mg BID	Raltegravir AUC increased 73%; Cmax increased 89%; Cmin decreased 44%	Rifapentine	900 mg PO once weekly			Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine.
5915	Raltegravir MVC 300	Raltegravir	400 mg Q12H	Raltegravir AUC decreased 37%; Cmin decreased 28%; Cmax decreased 33%	Maraviroc	300 mg Q12H	Maraviroc Cmin decreased 21%; Cmax decreased 20%		Green: Administer standard doses	Administer standard doses
5931	Raltegravir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 316	Raltegravir	400 mg BID	Raltegravir AUC increased 134%	Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir	paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg BID			Green: Administer standard doses	Administer standard doses
5900	Raltegravir RFB 285	Raltegravir	400 mg BID	Raltegravir AUC increased 19%; Cmax increased 39%; Cmin decreased 20%	Rifabutin	300 mg daily x 14 d			Yellow: Adjust dosing	Administer standard doses
5916	Raltegravir Lamotrigine 301	Raltegravir	400 mg BID		Lamotrigine	100 mg	No significant change		Green: Administer standard doses	Administer standard doses
5932	Raltegravir CBZ 317	Raltegravir			Carbamazepine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Use alternative agents	Levitiracetam
5901	Raltegravir RPT 286	Raltegravir	400 mg BID	When given with rifapentine once weekly for 3 weeks raltegravir AUC increased 79%, Cmax increased 89% and Cmin decreased 12%. When given with rifapentine for 10 daily doses, Cmin decreased 41%	Rifapentine	900 mg once weekly for 3 weeks or 600 mg once daily for 10 scheduled doses (days 1, 4?8 and 11?14)		Potential for increased raltegravir adverse effects if given with rifapentine once weekly; potential for loss of antiviral response if rifapentine coadministered daily	Green: Administer standard doses	Adjust dosing to avoid reduced levels of raltegravir	When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine.
5917	Raltegravir Midazolam 302	Raltegravir	400 mg BID		Midazolam	2 mg x 1	No significant change		Green: Administer standard doses	Administer standard doses
5933	Raltegravir Eslicarbazepine 318	Raltegravir			Eslicarbazepine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Use alternative agents	Levitiracetam
5902	Raltegravir EFV 287	Raltegravir	1200 mg (HD) single dose	Raltegravir AUC decreased 14%	Efavirenz	600 mg daily	Not reported	Potential decrease in antiretroviral efficacy	Green: Administer standard doses	Administer standard doses
5918	Raltegravir Pravastatin 303	Raltegravir	400 mg BID	Raltegravir AUC no significant change; Cmax increased 31%; Cmin decreased 41%	Pravastatin	40 mg daily	No significant change		Green: Administer standard doses	Administer standard doses
5934	Raltegravir Phenobarbital 319	Raltegravir			Phenobarbital			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Use alternative agents	Levitiracetam
5663	Maraviroc DRV/c 48	Maraviroc			Darunavir / Cobicistat				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5648	Maraviroc RIF 33	Maraviroc	100 mg BID	Maraviroc AUC decreased 63%; Cmax decreased 66%; Cmin decreased 78%	Rifampin	600 mg daily	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If also including a strong CYP3A4 inhibitor in the regimen, consider using an alternative agent due to difficulty predicting maraviroc concentrations.
5664	Maraviroc DRV 49	Maraviroc	300 mg daily	Maraviroc Cmin increased 16%; Cmax no significant change (when compared to maraviroc 300 mg BID without darunavir / ritonavir in separate control arm)	Darunavir	800 / 100 mg BID	Not reported		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5649	Maraviroc RIF 34	Maraviroc	200 mg BID	Maraviroc AUC increased 4%; Cmax decreased 3% when compared to maraviroc 100 mg BID given alone.	Rifampin	600 mg daily	Not reported		Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If also including a strong CYP3A4 inhibitor in the regimen, consider using an alternative agent due to difficulty predicting maraviroc concentrations.
5665	Maraviroc Clarithromycin 50	Maraviroc			Clarithromycin			Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce maraviroc dose to 150 mg BID
5650	Maraviroc EFV 35	Maraviroc	100 mg BID	Maraviroc AUC decreased 45%; Cmax decreased 51%	Efavirenz	600 mg daily	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
5666	Maraviroc Itraconazole 51	Maraviroc			Itraconazole			Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce maraviroc dose to 150 mg BID
5651	Maraviroc EFV 36	Maraviroc	200 mg BID	Maraviroc AUC increased 15%; Cmax increased 16% when compared to maraviroc 100 mg BID given alone.	Efavirenz	600 mg daily	Not reported		Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
5667	Maraviroc Posaconazole 52	Maraviroc			Posaconazole			Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce maraviroc dose to 150 mg BID
5652	Maraviroc CBZ 37	Maraviroc			Carbamazepine			Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
5668	Maraviroc Voriconazole 53	Maraviroc			Voriconazole			Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce maraviroc dose to 150 mg BID
5653	Maraviroc ETR 38	Maraviroc	300 mg BID	Maraviroc AUC decreased 53%; Cmin decreased 39%	Etravirine	200 mg BID	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
5669	Maraviroc Voriconazole 54	Maraviroc			Voriconazole			Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce maraviroc dose to 150 mg BID
5654	Maraviroc Phenobarbital 39	Maraviroc			Phenobarbital			Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
5670	Maraviroc RFB 55	Maraviroc	300 mg BID	Maraviroc AUC no change; Cmin decreased 30%	Rifabutin	300 mg daily	Not reported		Green: Administer standard doses	Administer standard doses
5655	Maraviroc Phenytoin 40	Maraviroc			Phenytoin			Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
5671	Maraviroc NVP 56	Maraviroc	300 mg single dose	Maraviroc AUC no change; Cmax increased 54%	Nevirapine	200 mg BID	Not reported		Green: Administer standard doses	Administer standard doses
5656	Maraviroc Ketoconazole 41	Maraviroc	100 mg BID	Maraviroc AUC increased 400%; Cmax increased 238%; Cmin increased 275%	Ketoconazole	400 mg daily	Not reported	Increased maraviroc effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5672	Maraviroc RAL 57	Maraviroc	300 mg BID	Maraviroc AUC decreased 14%; Cmax decreased 21%	Raltegravir	400 mg BID	Raltegravir AUC decreased 37%; Cmin decreased 27%		Green: Administer standard doses	Administer standard doses
5657	Maraviroc ATV/c 42	Maraviroc			Atazanavir / Cobicistat			Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5673	Maraviroc RPT 58	Maraviroc			Rifapentine			Potential decrease in antiretroviral efficacy	Green: Administer standard doses	Do not coadminister: Potential for reduced levels of maraviroc	Use alternative agents
5658	Maraviroc Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 43	Maraviroc			Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide			Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5674	Maraviroc Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 59	Maraviroc			Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir			Potential maraviroc-associated adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of maraviroc	Use alternative agents
5659	Maraviroc ATV 44	Maraviroc	300 mg BID	Maraviroc AUC increased 257%; Cmax increased 109%	Atazanavir	400 mg daily	Not reported	Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5675	Maraviroc St. John's Wort (Hypericum perforatum) 60	Maraviroc			St. John's Wort			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of maraviroc	Use alternative agents
5660	Maraviroc ATV/r 45	Maraviroc	300 mg BID	Maraviroc AUC increased 388%; Cmax increased 167%	Atazanavir	300 mg / 100 mg daily	Not reported	Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5676	Maraviroc Eslicarbazepine 61	Maraviroc			Eslicarbazepine			Potential decrease in antiretroviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
5661	Maraviroc DRV/r 46	Maraviroc	150 mg BID	Maraviroc AUC increased 305%; Cmax increased 129%	Darunavir	600 mg / 100 mg BID	Not reported	Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5677	Maraviroc Oxcarbazepine 62	Maraviroc			Oxcarbazepine			Potential decrease in antiretroviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
5662	Maraviroc RTV 47	Maraviroc	100 mg BID	Maraviroc AUC increased 161%; Cmax increased 28%	Ritonavir	100 mg BID	Not reported	Potential maraviroc-associated adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Reduce dose of maraviroc to 150 mg BID
5631	Fostemsavir RAL + TDF 16	Fostemsavir	1200 mg once daily	Temsavir Cmax increased 23%, AUC increased 7%, Cmin increased 17%	Raltegravir, Tenofovir Disoproxil Fumarate	RAL 400 mg BID, TDF 300 mg once daily	Not reported		Green: Administer standard doses	Administer standard doses
5647	Fostemsavir Simvastatin 32	Fostemsavir			Simvastatin			Increased statin exposure and risk of statin associated adverse events	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
5616	Fostemsavir RFB + RTV 1	Fostemsavir	600 mg BID	Temsavir Cmax increased 50%, AUC increased 66%, Cmin increased 158%	Rifabutin + Ritonavir	RFB 150 mg once daily, RTV 100 mg once daily	Not reported		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use standard dose rifabutin if coadministering with fostemsavir. If using fostemsavir in combination with a ritonavir boosted protease inhibitor, lower rifabutin dose to 150 mg daily.
5632	Fostemsavir CBZ 17	Fostemsavir			Carbamazepine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of temsavir	Contraindicated. Use alternative agents.
5617	Fostemsavir RFB 2	Fostemsavir	600 mg BID	Temsavir Cmax decreased 27%, AUC decreased 30%, Cmin decreased 41%	Rifabutin	300 mg once daily	Not reported		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use standard dose rifabutin if coadministering with fostemsavir. If using fostemsavir in combination with a ritonavir boosted protease inhibitor, lower rifabutin dose to 150 mg daily.
5633	Fostemsavir Enzalutamide 18	Fostemsavir			Enzalutamide			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of temsavir	Contraindicated. Use alternative agents.
5618	Fostemsavir Rosuvastatin 3	Fostemsavir	600 mg BID	Not studied	Rosuvastatin	10 mg single dose	Cmax increased 78%, AUC increased 69%	Increased statin exposure and risk of statin associated adverse events	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rosuvastatin	If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
5634	Fostemsavir Mitotane 19	Fostemsavir			Mitotane			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of temsavir	Contraindicated. Use alternative agents.
5619	Fostemsavir TDF 4	Fostemsavir	600 mg BID	Temsavir Cmax decreased 1%, Cmin increased 13%	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increased 18%, AUC increased 19%, Cmin increased 28%		Green: Administer standard doses	Administer standard doses
5635	Fostemsavir Phenobarbital 20	Fostemsavir			Phenobarbital			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of temsavir	Contraindicated. Use alternative agents.
5620	Fostemsavir ETR 5	Fostemsavir	600 mg BID	Temsavir Cmax decreased 48%, AUC decreased 50%, Cmin decreased 48%	Etravirine	200 mg BID	Etravirine Cmax increased 11%, AUC increased 11%, Cmin increased 14%		Green: Administer standard doses	Administer standard doses
5636	Fostemsavir Phenytoin 21	Fostemsavir			Phenytoin			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of temsavir	Contraindicated. Use alternative agents.
5621	Fostemsavir ATV/r 6	Fostemsavir	600 mg BID	Temsavir Cmax increased 68%, AUC increased 54%, Cmin increased 57%	Atazanavir	ATV 300mg, / r 100mg once daily	ATV: Cmax increased 3%, AUC increased 9%, Cmin increased 19%; / r: Cmax increased 2%, AUC increased 7%, Cmin increased 22%		Green: Administer standard doses	Administer standard doses
5637	Fostemsavir St. John's Wort (Hypericum perforatum) 22	Fostemsavir			St. John's Wort			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of temsavir	Contraindicated. Use alternative agents.
5622	Fostemsavir DRV/r 7	Fostemsavir	600 mg BID	Temsavir Cmax increased 52%, AUC increased 63%, Cmin increased 88%	Darunavir	DRV 600mg twice daily, / r 100mg twice daily	DRV no significant change. Ritonavir AUC increased 15%, Cmin increased 19%		Green: Administer standard doses	Administer standard doses
5638	Fostemsavir RPT 23	Fostemsavir			Rifapentine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of temsavir	Contraindicated. Use alternative agents.
5623	Fostemsavir DRV/r + ETR 8	Fostemsavir	600 mg BID	Temsavir Cmax increased 53%, AUC increased 34%, Cmin increased 33%	Darunavir	DRV 600mg twice daily, / r 100mg twice daily, ETR 200mg twice daily	DRV and ritonavir no significant changes. Etravirine Cmax increased 18%, AUC increased 28%, Cmin increased 28%.		Green: Administer standard doses	Administer standard doses
5639	Fostemsavir RIF 24	Fostemsavir	1200 mg once daily	Temsavir Cmax decreased 76%, AUC decreased 82%	Rifampin	600 mg once daily	Not reported	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of temsavir	Contraindicated. Use alternative agents.
5624	Fostemsavir RTV 9	Fostemsavir	600 mg BID	Temsavir Cmax increased 53%, AUC increased 45%, Cmin increased 44%	Ritonavir	100 mg once daily	Not reported		Green: Administer standard doses	Administer standard doses
5640	Fostemsavir Ethinyl estradiol / Norethindrone acetate 25	Fostemsavir	600 mg BID	Not reported	Ethinyl estradiol / Norethindrone acetate	0.030 / 1.5mg once daily	EE: Cmax increased 39%, AUC increased 40%; NE: Cmax increased 8%, AUC increased 8%	Increased ethinyl estradiol exposure and increased risk of thromboembolic events	Orange: Minimal data to guide interaction	Minimal data to guide interaction, weigh risks and benefits of using this combination	If co-adminstering, ethinyl estradiol daily dose should not exceed 30 mcg. Further caution advised if patient is at increased risk for thromboembolic events.
5625	Fostemsavir Cobi 10	Fostemsavir	600 mg BID	Temsavir Cmax increased 71%, AUC increased 93%, Cmin increased 136%	Cobicistat	150 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5641	Fostemsavir SOF/VEL/VOX 26	Fostemsavir			Sofosbuvir / Velpatasvir / Voxilaprevir			Increased exposure of voxilaprevir and risk of ALT elevations	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits benefit	Avoid combination; use alternative HCV regimen
5626	Fostemsavir DRV/c 11	Fostemsavir	600 mg BID	Temsavir Cmax increased 79%, AUC increased 97%, Cmin increased 124%	Darunavir / Cobicistat	800 / 150 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5642	Fostemsavir Elbasvir / grazoprevir 27	Fostemsavir			Elbasvir / Grazoprevir			Potentially increased exposure of grazoprevir and risk of ALT elevations	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits benefit	Avoid combination; use alternative HCV regimen
5627	Fostemsavir Buprenorphine / naloxone 12	Fostemsavir	600 mg BID	Not studied	Buprenorphine / naloxone	8mg / 2mg to 24mg / 6mg once daily, individual dosing	Buprenorphine Cmax increased 24%, AUC increased 30%, Cmin increased 39%. Norbuprenorphine Cmax increased 24%, AUC increased 39%, Cmin increased 39%		Green: Administer standard doses	Administer standard doses
5643	Fostemsavir Doxorubicin 28	Fostemsavir			Doxorubicin			Increased exposure of doxorubicin	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits benefit	If co-adminstering, monitor for adverse effects
5628	Fostemsavir MVC 13	Fostemsavir	600 mg BID	Temsavir Cmax increased 13%, AUC increased 10%, Cmin decreased 10%	Maraviroc	300 mg BID	Maraviroc AUC increased 25%, Cmin increased 37%		Green: Administer standard doses	Administer standard doses
5644	Fostemsavir Atorvastatin 29	Fostemsavir			Atorvastatin			Increased statin exposure and risk of statin associated adverse events	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
5629	Fostemsavir Methadone 14	Fostemsavir	600 mg BID	Not studied	Methadone	40-120mg once daily, individual dosing	Methadone R(-): Cmax increased 15%, AUC increased 13%. Methadone S(+): Cmax increased 15%, AUC increased 15%, Cmin increased 10%. Methadone (total): Cmax increased 25%, AUC increased 14%, Cmin increased 10%		Green: Administer standard doses	Administer standard doses
5645	Fostemsavir Fluvastatin 30	Fostemsavir			Fluvastatin			Increased statin exposure and risk of statin associated adverse events	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
5630	Fostemsavir Famotidine 15	Fostemsavir	600 mg BID	Temsavir Cmax increased 1%, AUC increased 4%, Cmin decreased 10%	Famotidine	40mg single dose	Not reported		Green: Administer standard doses	Administer standard doses
5646	Fostemsavir Pitavastatin 31	Fostemsavir			Pitavastatin			Increased statin exposure and risk of statin associated adverse events	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
5951	Cabotegravir Oxcarbazepine 336	Cabotegravir		Not studied	Oxcarbazepine		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5952	Cabotegravir Phenobarbital 337	Cabotegravir		Not studied	Phenobarbital		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5953	Cabotegravir Phenytoin 338	Cabotegravir		Not studied	Phenytoin		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5954	Cabotegravir Primidone 339	Cabotegravir		Not studied	Primidone		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5955	Cabotegravir RPT 340	Cabotegravir		Not studied	Rifapentine		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5956	Cabotegravir St. John's Wort (Hypericum perforatum) 341	Cabotegravir		Not studied	St. John's Wort		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5941	Cabotegravir Aluminum and magnesium hydroxide antacid 326	Cabotegravir		Not studied	Aluminum and magnesium hydroxide antacid		Not studied		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of cabotegravir	Administer antacids by at least 2 hours before or 4 hours after oral CAB
5957	Cabotegravir Griseofulvin 342	Cabotegravir		Not studied	Griseofulvin		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5942	Cabotegravir RFB 327	Cabotegravir	30 mg once daily	Cmax decreased 17%, AUC decreased 23%, Cmin decreased 26%	Rifabutin	300 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5958	Cabotegravir RIF 343	Cabotegravir	30 mg single dose	Cmax decreased 6%, AUC decreased 59%, Cmin decreased 50%	Rifampin	600 mg once daily	Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of CAB	Contraindicated. Use alternative agents.
5943	Cabotegravir RPV 328	Cabotegravir	30 mg once daily	Cmax increased 5%, AUC increased 12%, Cmin increased 14%	Rilpivirine	25 mg once daily	Cmax decreased 4%, AUC decreased 1%, Cmin decreased 8%		Green: Administer standard doses	Administer standard doses
5944	Cabotegravir EE/NGM 329	Cabotegravir	30 mg once daily	Not studied	Ethinyl estradiol / Norgestimate	0.03mg once daily	Cmax decreased 8%, AUC increased 2%		Green: Administer standard doses	Administer standard doses
5945	Cabotegravir LNG 330	Cabotegravir	30 mg once daily	Not studied	Levonorgestrel	0.15 mg once daily	Cmax increased 5%, AUC increased 12%, Cmin increased 7%		Green: Administer standard doses	Administer standard doses
5946	Cabotegravir Midazolam 331	Cabotegravir	30 mg once daily	Not studied	Midazolam	3mg	Cmax increased 9%, AUC increased 10%		Green: Administer standard doses	Administer standard doses
5947	Cabotegravir ETR 332	Cabotegravir	30 mg once daily	Cmax increased 4%, AUC increased 1%	Etravirine	200 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5948	Cabotegravir CBZ 333	Cabotegravir		Not studied	Carbamazepine		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5949	Cabotegravir Enzalutamide 334	Cabotegravir		Not studied	Enzalutamide		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
5950	Cabotegravir Eslicarbazepine 335	Cabotegravir		Not studied	Eslicarbazepine		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Contraindicated. Use alternative agents.
6838	Lenacapavir Buspirone	Lenacapavir			Buspirone			Potential increased risk of buspirone adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with lowest dose and titrate to clinical effect. Monitor for buspirone-related adverse events.		Sunlenca Product Label
6854	Lenacapavir Disopyramide	Lenacapavir			Disopyramide			Potential increased risk of disopyramide adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of disopyramide	Use alternative agents.		DHHS Adult ARV Guidelines
6870	Lenacapavir Hydrocortisone	Lenacapavir			Hydrocortisone			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-administering, initiate with the lowest starting dose and titrate to clinical effect. Monitor for hydrocortisone-related adverse effects.		DHHS Adult ARV Guidelines
6886	Lenacapavir Nevirapine	Lenacapavir			Nevirapine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Use alternative agents		DHHS Adult ARV Guidelines
6902	Lenacapavir Rifabutin	Lenacapavir			Rifabutin			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Use alternative agents		Sunlenca Product Label
6918	Lenacapavir Triamcinolone	Lenacapavir			Triamcinolone			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If used for local injections, monitor for corticosteroid-related adverse effects (e.g. Cushing's syndrome, adrenal insufficiency).		Sunlenca Product Label
6723	Lenacapavir Rifampin	Lenacapavir	300 mg orally x 1	AUC decreased 84%; Cmax decreased 55%	Rifampin	600 mg daily (fasted)	Not reported	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: decreased levels of lenacapavir	Use alternative agents		Sunlenca Product Label
6839	Lenacapavir Carbamazepine	Lenacapavir			Carbamazepine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Contraindicated. Use alternative agents.		DHHS Adult ARV Guidelines
6855	Lenacapavir Dronedarone	Lenacapavir			Dronedarone			Potential increased risk of dronedarone adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider using alternative cardiac medication or ARV. If coadministering, monitor for dronedarone adverse effects.		Sunlenca Product Label
6871	Lenacapavir Ivabradine	Lenacapavir			Ivabradine			Potential increased risk of ivabradine adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of ivabradine	Use alternative agents.		DHHS Adult ARV Guidelines
6887	Lenacapavir Nifedipine	Lenacapavir			Nifedipine			Potential increased risk of nifedipine adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for cardiac medication adverse effects (e.g. hypotension)		Sunlenca Product Label
6903	Lenacapavir Rifapentine	Lenacapavir			Rifapentine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Use alternative agents		DHHS Adult ARV Guidelines
6919	Lenacapavir Triazolam	Lenacapavir			Triazolam			Increased risk of triazolam adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for triazolam adverse effects (e.g. sedation, respiratory depression).		DHHS Adult ARV Guidelines
6725	Lencapavir Alfuzosin	Lenacapavir			Alfuzosin			Potential for increased alfuzosin effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider alternative to alfuzosin. If coadministered, monitor for adverse effects (e.g. hypotension)		DHHS Adult ARV Guidelines
6840	Lenacapavir Cisapride	Lenacapavir			Cisapride			Potential increased risk of cisapride adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of cisapride	Contraindicated. Use alternative agents		DHHS Adult ARV Guidelines
6856	Lenacapavir Edoxaban	Lenacapavir			Edoxaban			Potential increased risk of bleeding	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution. Monitor for edoxaban adverse effects (e.g. bleeding)		Sunlenca Product Label
6872	Lenacapavir Lamborexant	Lenacapavir			Lamborexant			Potential increased risk of excessive sedation	Red: Avoid combination	Do not coadminister: potentially increased levels of lamborexant	Use alternative agents.		DHHS Adult ARV Guidelines
6888	Lenacapavir Oxcarbazepine	Lenacapavir			Oxcarbazepine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Use alternative agents		Sunlenca Product Label
6904	Lenacapavir Rimegepant	Lenacapavir			Rimegepant			Potential increased risk of rimegepant adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, avoid taking a second dose of rimegepant within 48 hours		Sunlenca Product Label
6920	Lenacapavir Ubrogepant	Lenacapavir			Ubrogepant			Potential increased risk of ubrogepant adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, avoid taking a second dose of ubrogepant within 24 hours		Sunlenca Product Label
6726	Lenacapavir Alprazolam	Lenacapavir			Alprazolam			Potential increased risk of sedation, respiratory depression	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, use lowest effective dose and monitor for alprazolam adverse effects		DHHS Adult ARV Guidelines
6841	Lenacapavir Clonazepam	Lenacapavir			Clonazepam			Potential increased risk of sedation, respiratory depression	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider alternative benzodiazepines. If coadministering, use lowest effective dose and monitor for clonazepam adverse effects.	Oxazepam, lorazepam, temazepam	DHHS Adult ARV Guidelines
6857	Lenacapavir Efavirenz	Lenacapavir	300 mg orally x 1	AUC decreased 55%; Cmax decreased 36%	Efavirenz	600 mg daily (fasted)	Not reported	Potential for loss of lenacapavir efficacy	Red: Avoid combination	Do not coadminister: decreased levels of lenacapavir	Use alternative agents		DHHS Adult ARV Guidelines
6873	Lenacapavir Lidocaine	Lenacapavir			Lidocaine			Potential increased risk of lidocaine adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider using alternative antiarrythmic or ARV. If coadministering, monitor for lidocaine adverse effects.		DHHS Adult ARV Guidelines
6889	Lenacapavir Oxycodone	Lenacapavir			Oxycodone			Increased risk of oxycodone adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor therapeutic effects and adverse reactions (e.g. sedation, respiratory depression)		Sunlenca Product Label
6905	Lenacapavir Rivaroxaban	Lenacapavir			Rivaroxaban			Potential increased risk of bleeding	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution. Monitor for rivaroxaban adverse effects (e.g. bleeding). Avoid coadministration in persons with renal impairment (CrCL 15 - 80 ml/min) due to increased risk of bleeding.		Sunlenca Product Label
6921	Lenacapavir Vardenafil	Lenacapavir			Vardenafil			Increased risk of vardenafil adverse effects (e.g. flushing, headache, hypotension)	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-administering vardenafil for erectile dysfunction, dose should not exceed 5 mg per 24 hour. Monitor for adverse effects.		DHHS Adult ARV Guidelines
6727	Lenacapavir Amiodarone	Lenacapavir			Amiodarone			Potential increased risk of amiodarone and lenacapavir adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of amiodarone	Use alternative agents.		DHHS Adult ARV Guidelines
6842	Lenacapavir Clopidogrel	Lenacapavir			Clopidogrel			Potential increased risk of bleeding	Yellow: Adjust dosing	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative ARV or antiplatelet agents. If coadministering, monitor for clopidogrel-related adverse events (e.g. bleeding)		Sunlenca Product Label
6858	Lenacapavir Eplerenone	Lenacapavir			Eplerenone			Potential increased risk of eplerenone adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering in the setting of post-MI heart failure, eplerenone dose not to exceed 25 mg daily. If coadministered for hypertension, initiate eplerenone at 25mg daily. Dose not to exceed 25 mg twice daily.		Sunlenca Product Label
6874	Lenacapavir Lomitapide	Lenacapavir			Lomitapide			Potential increased risk of lomitapide adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of lomitapide	Contraindicated. Use alternative agents		Sunlenca Product Label
6890	Lenacapavir Phenobarbital	Lenacapavir			Phenobarbital			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Use alternative agents		Sunlenca Product Label
6906	Lenacapavir Rosuvastatin	Lenacapavir		Not reported	Rosuvastatin	5 mg orally x 1	AUC increased 31%; Cmax increased 57%	Potential for increased rosuvastatin adverse effects (e.g. myalgias, increased transaminases)	Green: Administer standard doses	Administer standard doses			Sunlenca Product Label
6922	Lenacapavir Verapamil	Lenacapavir			Verapamil			Potential increased risk of verapamil adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for cardiac medication adverse effects (e.g. hypotension)		Sunlenca Product Label
6728	Lenacapavir Amlodipine	Lenacapavir			Amlodipine			Potential increased risk of amlodipine adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for cardiac medication adverse effects (e.g. hypotension)		DHHS Adult ARV Guidelines
6843	Lenacapavir Cobicistat	Lenacapavir	300 mg orally x 1	AUC increased 128%; Cmax increased 110%	Cobicistat	150 mg once daily (in fed state)	Not reported	Increased risk of lenacapavir adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Management of interaction depends on component that cobicistat is serving as a PK booster for. See partner antiretroviral for further details.		DHHS Adult ARV Guidelines
6859	Lenacapavir Ergotamine	Lenacapavir			Ergotamine			Increased risk of ergotamine adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of ergotamine	Use alternative agents		DHHS Adult ARV Guidelines
6875	Lenacapavir Lovastatin	Lenacapavir			Lovastatin			Increased risk of lovastatin adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Initiate lovastatin with the lowest starting dose and titrate to clinical effect. Monitor for adverse effects of lovastatin (e.g. myopathy, elevated transaminases).		DHHS Adult ARV Guidelines
6891	Lenacapavir Phenytoin	Lenacapavir			Phenytoin			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Contraindicated. Use alternative agents.		DHHS Adult ARV Guidelines
6907	Lenacapavir Sildenafil	Lenacapavir			Sildenafil			Increased risk of sildenafil adverse effects (e.g. flushing, headache, hypotension).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH): Concomitant administration of SUNLENCA with tadalafil for the treatment of PAH is not recommended. Use of PDE-5 inhibitors for erectile dysfunction (ED): Refer to the prescribing information of sildenafil for dose recommendations. Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH): Do not coadminaster sildenafil with Lenacapavir. Use of PDE-5 inhibitors for erectile dysfunction (ED): Adjust dosing to avoid increased levels sildenafil		Sunlenca Product Label
6923	Lenacapavir Voriconazole	Lenacapavir	300 mg orally x 1	AUC increased 41%; Cmax increased 9%	Voriconazole	400 mg BID x 2 days then 200 mg BID	Not reported	No clinically significant effect expected	Green: Administer standard doses	Administer standard doses			DHHS Adult ARV Guidelines
6729	Lenacapavir Apixaban	Lenacapavir			Apixaban			Potential increased risk of bleeding	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution. Monitor for apixaban adverse effects (e.g. bleeding)		DHHS Adult ARV Guidelines
6844	Lenacapavir Colchicine	Lenacapavir			Colchicine			Potential increased risk of GI adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If using for gout flare may coadminister a single dose of 1.2 mg. May not repeat dose for at least 3 days. If using for Familiar Mediterranean Fever do not exceed colchicine dose of 1.2 mg daily.		DHHS Adult ARV Guidelines
6860	Lenacapavir Eslicarbazepine	Lenacapavir			Eslicarbazepine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Use alternative agents.		DHHS Adult ARV Guidelines
6876	Lenacapavir Lumateperone	Lenacapavir			Lumateperone			Potential increased risk of lumateperone adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, reduce lumateperone dose to 21 mg		DHHS Adult ARV Guidelines
6892	Lenacapavir Pimozide	Lenacapavir			Pimozide			Potential increased risk of pimozide adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of pimozide	Contraindicated. Use alternative agents		Sunlenca Product Label
6908	Lenacapavir Simvastatin	Lenacapavir			Simvastatin			Increased risk of simvastatin adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Initiate simvastatin with the lowest starting dose and titrate to clinical effect. Monitor for adverse effects of lovastatin (e.g. myopathy, elevated transaminases).		DHHS Adult ARV Guidelines
6924	Lenacapavir Warfarin	Lenacapavir			Warfarin			Potential increased risk of bleeding	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution. Monitor INR and for warfarin adverse effects (e.g. bleeding)		DHHS Adult ARV Guidelines
6829	Lenacapavir Artemether/Lumefantrine	Lenacapavir			Artemether / Lumefantrine			Potential increased risk of lumefantrine adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for lumefantrine adverse effects (e.g. QT prolongation)		Sunlenca Product Label
6845	Lenacapavir Cyclosporine	Lenacapavir			Cyclosporine			Potential increased risk of immunosuppressant adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary.		Sunlenca Product Label
6861	Lenacapavir Eszopiclone	Lenacapavir			Eszopiclone			Potential increased risk of excessive sedation	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate lowest starting dose. Monitor for excessive sedation.		DHHS Adult ARV Guidelines
6877	Lenacapavir Lurasidone	Lenacapavir			Lurasidone			Potential increased risk of lurasidone adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If initiating lurasidone in a person stable on lenacapavir, recommended starting dose is 20 mg daily, not to exceed 80 mg daily. If initiating lenacapavir in a person stable on lurasidone, reduce lurasidone dose by 50%		DHHS Adult ARV Guidelines
6893	Lenacapavir Pitavastatin	Lenacapavir	600 mg BID x 2 days, then 600 mg daily x 1	Not reported	Pitavastatin	2 mg x 1 (with food, simultaneous administration with oral LEN)	AUC increased 11%	No clinically significant effect expected	Green: Administer standard doses	Administer standard doses			Sunlenca Product Label
6909	Lenacapavir Sirolimus	Lenacapavir			Sirolimus			Potential increased risk of immunosuppressant adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary.		Sunlenca Product Label
6925	Lenacapavir Zolpidem	Lenacapavir			Zolpidem			Potential increased risk of excessive sedation	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate lowest starting dose. Monitor for excessive sedation.		DHHS Adult ARV Guidelines
6830	Lenacapavir Atazanavir/cobicistat	Lenacapavir	300 mg orally x 1	AUC increased 321%; Cmax increased 560%	Atazanavir / Cobicistat	300/150 mg daily (fed state)	Not reported	Potential for increased atazanavir adverse effects (e.g. hyperbilirubinemia, gastrointestinal effects).	Red: Avoid combination	Do not coadminister: increased levels of atazanavir	Use alternative agents		Sunlenca Product Label
6846	Lenacapavir Dabigatran	Lenacapavir			Dabigatran			Potential increased risk of bleeding	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution. Monitor for dabigatran adverse effects (e.g. bleeding)		DHHS Adult ARV Guidelines
6862	Lenacapavir Ethosuximide	Lenacapavir			Ethosuximide			Potential increased ethosuximide effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor for ethosuximide-related adverse events.		DHHS Adult ARV Guidelines
6878	Lenacapavir Mavacamten	Lenacapavir			Mavacamten			Potential increased risk of mavacamten adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If initiating lenacapavir in patients stable on mavacamten, reduce mavacamten dose by one level (e.g. 15 mg to 10 mg, 10 mg to 5 mg, 5 mg to 2.5 mg). If initiating mavacamten in patients stable on lenacapavir, use typical starting dose (5 mg daily).		DHHS Adult ARV Guidelines
6894	Lenacapavir Praziquantel	Lenacapavir			Praziquantel			Potential increased risk of praziquantel adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: risks likely to outweigh benefits	Consider alternative antiretroviral. If coadministration is necessary, monitor for praziquantel adverse effects.		DHHS Adult ARV Guidelines
6910	Lenacapavir St. John's Wort	Lenacapavir			St. John's Wort			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Contraindicated. Use alternative agents.		DHHS Adult ARV Guidelines
6926	Lenacapavir Midazolam 1	Lenacapavir	600 mg BID x 2 days, then 600 mg daily x 1	Not reported	Midazolam	2.5 mg orally x 1 with food, administered 1 day after LEN	AUC increased 308%; Cmax increased 116%. AUC for 1-hydroxy metabolite decreased 16%.	Potential for increased sedation	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-administering, monitor for excess sedation and adjust dose accordingly		DHHS Adult ARV Guidelines
6831	Lenacapavir Atazanavir/ritonavir	Lenacapavir			Atazanavir, Ritonavir			Potential increase in lenacapavir adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of lenacapavir	Use alternative agents		DHHS Adult ARV Guidelines
6847	Lenacapavir Daridorexant	Lenacapavir			Daridorexant			Potential increased risk of excessive sedation	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, maximum dose of daridorexant is 25 mg.		Sunlenca Product Label
6863	Lenacapavir Etravirine	Lenacapavir			Etravirine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: potentially reduced levels of lenacapavir	Use alternative agents.		DHHS Adult ARV Guidelines
6879	Lenacapavir Mefloquine	Lenacapavir			Mefloquine			Potential increased risk of mefloquine adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for mefloquine adverse effects (e.g. QT prolongation)		Sunlenca Product Label
6895	Lenacapavir Prednisolone	Lenacapavir			Prednisolone			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-administering, initiate with the lowest starting dose and titrate to clinical effect. Monitor for corticosteroid-related adverse effects (e.g. Cushing's syndrome, adrenal insufficiency).		DHHS Adult ARV Guidelines
6911	Lenacapavir Suvorexant	Lenacapavir			Suvorexant			Potential increased risk of excessive sedation	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate dose at 5 mg daily. May increase to 10 mg daily if not effective. Monitor for excessive sedation.		DHHS Adult ARV Guidelines
6927	Lenacapavir Pitavastatin 1	Lenacapavir	600 mg BID x 2 days, then 600 mg daily x 1	Not reported	Pitavastatin	2 mg x 1 (with food), administered 3 days after LEN	AUC decreased 4%	No clinically significant effect expected	Green: Administer standard doses	Administer standard doses			DHHS Adult ARV Guidelines
6832	Lenacapavir Avanafil	Lenacapavir			Avanafil			Potential increased risk of avanafil adverse effects (e.g. hypotension)	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, avanafil dose should not exceed 50 mg in 24 hours		DHHS Adult ARV Guidelines
6848	Lenacapavir Darunavir/cobicistat	Lenacapavir	300 mg orally x 1	AUC increased 94%; Cmax increased 130%	Darunavir / Cobicistat	800/150 mg once daily (in fed state)	Not reported	No clinically significant effect expected	Green: Administer standard doses	Administer standard doses			Sunlenca Product Label
6864	Lenacapavir Everolimus	Lenacapavir			Everolimus			Potential increased risk of immunosuppressant adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary.		Sunlenca Product Label
6880	Lenacapavir Methadone	Lenacapavir			Methadone			Unknown effect on methadone	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If initiating methadone in a person already on lenacapavir, start with lowest feasible dose and titrate to clinical effect. If initiating lenacapavir in a person stable on methadone, dose adjustment of methadone may be required. Monitor for clinical efficacy and adverse effects (e.g. sedation, respiratory depression).		Sunlenca Product Label
6896	Lenacapavir Prednisone	Lenacapavir			Prednisone			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-administering, initiate with the lowest starting dose and titrate to clinical effect. Monitor for corticosteroid-related adverse effects (e.g. Cushing's syndrome, adrenal insufficiency).		DHHS Adult ARV Guidelines
6912	Lenacapavir Tacrolimus	Lenacapavir			Tacrolimus			Potential increased risk of immunosuppressant adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary.		Sunlenca Product Label
6833	Lenacapavir Bedaquiline	Lenacapavir			Bedaquiline			Potential for increased bedaquiline levels	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider alternative agents. If coadministering, monitor LFTs and ECG.		DHHS Adult ARV Guidelines
6849	Lenacapavir Dexamethasone	Lenacapavir			Dexamethasone			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-administering, initiate with the lowest starting dose and titrate to clinical effect. Do not use doses of dexamethasone > 16 mg. Monitor for dexamethasone-related adverse effects.		DHHS Adult ARV Guidelines
6865	Lenacapavir Famotidine	Lenacapavir	300 mg orally x 1	AUC increased 28%	Famotidine	40 mg daily	Not reported	No clinically significant effect expected	Green: Administer standard doses	Administer standard doses			DHHS Adult ARV Guidelines
6881	Lenacapavir Methylergonovine	Lenacapavir			Methylergonovine			Increased risk of methylergonovine adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of methylergonovine	Use alternative agents		DHHS Adult ARV Guidelines
6897	Lenacapavir Primidone	Lenacapavir			Primidone			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: reduced levels of lenacapavir	Use alternative agents.		DHHS Adult ARV Guidelines
6913	Lenacapavir Tadalafil	Lenacapavir			Tadalafil			Increased risk of tadalafil adverse effects (e.g. flushing, headache, hypotension)	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Pulmonary arterial hypertension: coadministration of lenacapavir with tadalafil is not recommended. Erectile dysfunction: When used on an "as needed" basis, tadalafil dose should not exceed 10 mg every 72 hours. If used once daily (chronic administration), tadalafil dose should not exceed 2.5 mg daily.		Sunlenca Product Label
6834	Lenacapavir Betamethasone	Lenacapavir			Betamethasone			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If used for local injections, monitor for corticosteroid-related adverse effects (e.g. Cushing's syndrome, adrenal insufficiency).		DHHS Adult ARV Guidelines
6850	Lenacapavir Diazepam	Lenacapavir			Diazepam			Potential increased risk of sedation, respiratory depression	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider alternative benzodiazepines. If coadministering, use lowest effective dose and monitor for diazepam adverse effects.	Oxazepam, lorazepam, temazepam	Sunlenca Product Label
6866	Lenacapavir Felodipine	Lenacapavir			Felodipine			Potential increased risk of felodipine adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for cardiac medication adverse effects (e.g. hypotension)		Sunlenca Product Label
6882	Lenacapavir Methylprednisolone	Lenacapavir			Methylprednisolone			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If used for local injections, monitor for corticosteroid-related adverse effects (e.g. Cushing's syndrome, adrenal insufficiency).		Sunlenca Product Label
6898	Lenacapavir Propafenone	Lenacapavir			Propafenone			Potential increased risk of propafenone adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider using alternative antiarrhythmic or ARV. If coadministering, monitor for propafenone adverse effects.		DHHS Adult ARV Guidelines
6914	Lenacapavir Tenofovir alafenamide	Lenacapavir	600 mg BID x 2 days, then 600 mg daily x 1	Not reported	Tenofovir Alafenamide	25 mg x 1	TAF AUC increased 32%; Cmax increased 24%. TFV AUC increased 47%; Cmax increased 23%	No clinically significant effect expected	Green: Administer standard doses	Administer standard doses			DHHS Adult ARV Guidelines
6835	Lenacapavir Brexpiprazole	Lenacapavir			Brexpiprazole			Potential increased risk of brexpiprazole adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering in patients known to be poor CYP2D6 metabolizers, use 1/4 of brexpiprazole dose. Monitor for adverse events.		DHHS Adult ARV Guidelines
6851	Lenacapavir Digoxin	Lenacapavir			Digoxin			Potential increased risk of digoxin adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution and monitor digoxin therapeutic concentration		Sunlenca Product Label
6867	Lenacapavir Fentanyl	Lenacapavir			Fentanyl			Increased risk of fentanyl adverse effects	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor therapeutic effects and adverse reactions (e.g. sedation, respiratory depression)		DHHS Adult ARV Guidelines
6883	Lenacapavir Midazolam	Lenacapavir	600 mg BID x 2 days, then 600 mg daily x 1	Not reported	Midazolam	2.5 mg orally x 1, administered simultaneously with LEN	AUC increased 259%; Cmax increased 94%. AUC for 1-hydroxy metabolite decreased 24%.	Potential for increased sedation	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If co-administering, monitor for excess sedation and adjust dose accordingly		Sunlenca Product Label
6899	Lenacapavir Quetiapine	Lenacapavir			Quetiapine			Potential increased risk of quetiapine adverse effects (e.g. sedation, QT prolongation)	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider using alternative antipsychotics. If coadministering, consider quetiapine dose reduction and monitor for adverse effects.		DHHS Adult ARV Guidelines
6915	Lenacapavir Thioridazine	Lenacapavir			Thioridazine			Potential loss of antiviral efficacy	Yellow: Adjust dosing	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative antipsychotic		Sunlenca Product Label
6836	Lenacapavir Budesonide	Lenacapavir			Budesonide			Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).	Yellow: Adjust dosing	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate lowest starting dose and titrate to clinical effect. Monitor for adverse effects such as adrenal insufficiency and Cushing's syndrome.		Sunlenca Product Label
6852	Lenacapavir Dihydroergotamine	Lenacapavir			Dihydroergotamine			Increased risk of dihydroergotamine adverse effects	Red: Avoid combination	Do not coadminister: potentially increased levels of dihydroergotamine	Use alternative agents		DHHS Adult ARV Guidelines